2. Infection

Infection

Infection

Related Products

PDF 70.44 MB

Infection is a pathophysiological process that involves the invasion and colonization of a living organism (host) by disease-causing infectious agents, the reaction of host tissues to these agents and the toxins they produce, and the transmission of infectious agents to other hosts. Common infectious agents include viruses, viroids, prions, bacteria, nematodes, arthropods, and other macroparasites such as tapeworms. Hosts can fight infections using their immune system. Mammals often engage both innate and adaptive immune systems to eliminate infectious agents or inhibit their growth and transmission. When infection occurs, anti-infective drugs can suppress the infection. Several broad types of anti-infective drugs exist, depending on the type of organism targeted; they include antibacterial (antibiotic), antiviral, antifungal and antiparasitic agents.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-174456
    Succinate dehydrogenase-IN-10
    Succinate dehydrogenase-IN-10 (Compound B5) is a RsSDH (Succinate dehydrogenase of R. solani) inhibitor with an IC50 of 0.12 μM. Succinate dehydrogenase-IN-10 exhibits antifungal activity against R. solani (EC50 of 0.002 μg/mL) and P. pachyrhizi.
    Succinate dehydrogenase-IN-10
  • HY-17452B
    Cefditoren Pivoxil hydrochloride 1448435-17-3 98%
    Cefditoren Pivoxil (ME 1207) hydrochloride is a broad-spectrum, third-generation, oral cephalosporin antibacterial with enhanced stability against many common β lactamases. Cefditoren Pivoxil has activity against Gram-negative organisms and Gram-positive organisms. Cefditoren Pivoxil can be used in the research of infection diseases such as acute exacerbations of chronic bronchitis, community-acquired pneumonia (CAP), streptococcal pharyngitis/tonsillitis, or uncomplicated skin and skin structure infections.
    Cefditoren Pivoxil hydrochloride
  • HY-174804
    DHAD-IN-1 2803311-65-9
    DHAD-IN-1 (Compound I-6e) is a potent dihydroxyacid dehydratase (DHAD) inhibitor with a Ki value of 1 μM for Arabidopsis thaliana DHAD. DHAD-IN-1 exhibits 100% efficacy against weeds like Avena fatua and Setaria viridis. DHAD-IN-1 is promising for research of herbicides.
    DHAD-IN-1
  • HY-174814
    Jun15716 827034-42-4 98%
    Jun15716 is an Enterovirus (EVs) 2C protein (EVs 2C) inhibitor with Kis of 15.9, 44.2 and 17.8 μM for EV-D68, EV-A71 and CVB3, respectively. Jun15716 has a potent antiviral activity against EV-D68 US/MO/14-18947 and CVB3 Nancy cells (EC50s of 1.0 and 0.7 μM, respectively). Jun15716 can be used for viral infections research, such as meningitis, hand, foot and mouth disease (HFMD) and viral myocarditis.
    Jun15716
  • HY-174815
    Jun15799
    Jun15799 is an Enterovirus (EVs) 2C protein (EVs 2C) inhibitor with Kis of 0.8, 21.1 and 3.0 μM for EV-D68, EV-A71 and CVB3, respectively. Jun15799 has a significant antiviral activity against EV-D68 US/MO/14-18947, EV-A71 Tainan/4643/1998 and CVB3 Nancy cells (EC50s of 0.3, 11.4 and 0.3 μM, respectively). Jun15799 can be used for viral infections research, such as meningitis, hand, foot and mouth disease (HFMD) and viral myocarditis.
    Jun15799
  • HY-174831
    SDH-IN-28 98%
    SDH-IN-28 is a succinate dehydrogenase inhibitor with an IC50 value of 2.65 mg/L. SDH-IN-28 demonstrates broad-spectrum fungicidal efficacy, with EC50 values of 0.21 (Valsa mali), 0.95 (Botrytis cinerea), 0.64 (Rhizoctonia solani), 1.33 (Fusarium graminearum), and 0.66 mg/L (Gaeumannomyces graminis). SDH-IN-28 effectively prevents V. mali infection in apples.
    SDH-IN-28
  • HY-174852
    Antibacterial agent 285 2797056-04-1 98%
    Antibacterial agent 285 (Compound 3) is a cephalosporin antibiotic. Antibacterial agent 285 has significant antibacterial activity against gram-negative bacterium with MICs of 0.125-0.5, 0.125-0.5 and 0.125-2 μg/mL for carbapenem-resistant Acinetobacter baumannii (CRAB), Klebsiella pneumoniae (CRE) and Pseudomonas aeruginosa (CRPA), respectively. Antibacterial agent 285 can be used for bacterial infection research, such as complicated urinary tract infections (cUTI) and kidney infections.
    Antibacterial agent 285
  • HY-174856
    PROTAC HBeAg degrader-1 98%
    PROTAC HBeAg degrader-1 is a PROTAC targeting degradation agent for HBeAg. PROTAC HBeAg degrader-1 recruits the VHL E3 ligase but degrades HBV protein HBeAg through VHL-independent mechanism. PROTAC HBeAg degrader-1 decreases levels of secreted and intracellular HBeAg. PROTAC HBeAg degrader-1 can be used for the research of hepatitis B virus (HBV). (Structure Note: Pink: HBeAg ligand (HY-174857); Blue: VHL Ligand (HY-125845); Black: linker; E3-linker (HY-135045))
    PROTAC HBeAg degrader-1
  • HY-174998
    HIV-1 protease-IN-15 2986573-09-3
    HIV-1 protease-IN-15 (Compound 27) is an orally active and selective inhibitor targeting HIV-1 protease with a pIC50 value of 9.347. HIV-1 protease-IN-15 inhibits HIV protein maturation, blocks viral replication. HIV-1 protease-IN-15 is promising for research of HIV-1 infection.
    HIV-1 protease-IN-15
  • HY-175015
    SARS-CoV-2 Mpro-IN-46 1800004-01-6
    SARS-CoV-2 Mpro-IN-46 (Compound 12) is a SARS-CoV-2 main protease inhibitor with an IC50 of ∼25 μM. SARS-CoV-2 Mpro-IN-46 has potent antiviral activity with low cytotoxicity against SARS-CoV-2 (IC50: 7.4 μM). SARS-CoV-2 Mpro-IN-46 can be used for coronaviruses COVID-19 research.
    SARS-CoV-2 Mpro-IN-46
  • HY-175016
    NADH-IN-3
    NADH-IN-3 (Compound C4-1) is a NADH inhibitor with a MIC of 4 μg/mL (13.042 μM) for type II NADH dehydrogenase of Mycobacterium tuberculosis (Mtb). NADH-IN-3 significantly interrupts ATP synthesis, shows potent inhibitory effects against mono (Rifampicin (HY-B0272) and Isoniazid (HY-B0329)) and multi drug-resistant (Mtb) strains and an anti-bactericidal activity against HepG2 cells with low cytotoxicity (SI: 16.52).
    NADH-IN-3
  • HY-175024
    MC12
    MC12 is a thiazole-based derivative and a SARS-CoV-2 main protease inhibitor (IC50: 77.7 nM). MC12 exhibits inhibitory effects on both SARS-CoV and SARS-CoV-2 main proteases, with low cytotoxicity and good stability. MC12 can be used in the research of anti-COVID-19 drugs.
    MC12
  • HY-175031
    GRL-07524
    GRL-07524 (Compound 4e) is a potent inhibitor of HIV-1 protease (Ki = 0.22 nM). GRL-07524 contains oxaspirocyclic carbamates as the P2 ligands. GRL-07524 exhibits good antiviral activity with an EC50 = 210 nM. GRL-07524 binds to the HIV-1 PR active site in one of the four symmetry independent molecules along with key catalytic residues.
    GRL-07524
  • HY-175038
    Oomycete-IN-1 2945180-71-0
    Oomycete-IN-1 (Compound X4) is a selective inhibitor targeting the PH domain of PcORP1 in Phytophthora species. Oomycete-IN-1 shows EC50 values ranging from 1 to 4 μg/mL against six oomycetes. Oomycete-IN-1 disrupts lipid transport and metabolism, leading to mycelium hyperplasia and cell membrane ruffling in P. capsici. Oomycete-IN-1 can be used in the research of preventing and controlling oomycete diseases (such as P. capsici infection).
    Oomycete-IN-1
  • HY-17507E
    S-Pantoprazole sodium trihydrate 1416988-58-3 98%
    S-Pantoprazole (sodium trihydrate) is related to Pantoprazole (HY-17507) that plays an important roles in gastric acid secretion disorder-related diseases, or as proton pump inhibitor.
    S-Pantoprazole sodium trihydrate
  • HY-175165
    Jun6504 98%
    Jun6504 is an enterovirus 2C inhibitor. Jun6504 shows potent and broad-spectrum antiviral activity against multiple strains of EV-D68 (EC50 = 250 nM), EV-A71 (EC50 = 502.4 nM), and CVB3 (EC50 = 1049 nM). Jun6504 improves paralysis score and weight gain in a neonatal mouse model of EV-D68 infection. Jun6504 reduces viral titers in the spinal cord and the infected quadriceps muscle. Jun6504 can be used for EV-D68 antiviral research.
    Jun6504
  • HY-175169
    Urease-IN-21 98%
    Urease-IN-21 (Compound 11b) is a Urease inhibitor with an IC50 of 0.12  μM. Urease-IN-21 has potent antibacterial activity against helicobacter pylori (H. pylori) and inhibitor activity against P450 enzyme (CYP2C19, CYP2C9, and CYP3A4). Urease-IN-21 can be used for H. pylori infection research.
    Urease-IN-21
  • HY-17516R
    Tolfenpyrad (Standard) 129558-76-5 98%
    Tolfenpyrad (Standard) is the analytical standard of Tolfenpyrad (HY-17516). This product is intended for research and analytical applications. Tolfenpyrad is an orally active insecticide, acaricide and antibacterial agent. Tolfenpyrad inhibits Complex I in the mitochondrial respiratory electron transport chain, interfering with the cell respiration process. Tolfenpyrad has significant insecticidal activity against a variety of insect pests such as H. contortus, Coccinella septempunctata. Tolfenpyrad has antibacterial activity against Francisella novicida, with an IC50 of 1.2 µM or 1.5 µM.
    Tolfenpyrad (Standard)
  • HY-175181
    SufS-IN-1 167933-78-0 98%
    SufS-IN-1, a (2R,3R)-3-ethoxycarbonylaziridine-2-carboxylic acid (EAC), is a selective Cysteine desulfurase type II (SufS) inhibitor. SufS-IN-1 significantly inhibits the SufS activity by covalently binding to the cofactor PLP to form a stable PLP-ligand conjugates. SufS-IN-1 can be used for pathogenic microorganisms research, such as Plasmodium falciparum, Staphylococcus aureus and Mycobacterium tuberculosis.
    SufS-IN-1
  • HY-175183
    Antituberculosis agent-15
    Antituberculosis agent-15 (Compound 18c) is a selective antimycobacterial agent with MICs of 0.45 and 0.28  μM for M. tuberculosis H37Rv (ATCC 27294) and its wild-type H37Rv-LP (ATCC 25618), respectively. Antituberculosis agent-15 has potent intracellular inhibitory activities in macrophage infection models with IC50s of 0.16  μM. Antituberculosis agent-15 can be used for tuberculosis research.
    Antituberculosis agent-15
Cat. No. Product Name / Synonyms Application Reactivity